News

Biogasol attracts €15m
Enlarge image

FundingDenmarkCyprus

Biogasol attracts €15m

13.11.2012 - Danish Biogasol receives €15m equity and state money to test an lignocellulosic ethanol-production technology in a large-scale setting.

The renewable energy company BioGasol ApS from Ballerup has raised €15m. One third of the sum is new equity financing consisting of a co-investment by the current majority shareholder, Cyprus-based Fjord Capital Partners Ltd, and Unipension, a leading Danish pension fund managing assets of more than €12bn. €10m stems from a grant which has been approved by the Energy Technology Development and Demonstration Program (EUDP), a part of the Danish Energy Agency. BioGasol owns an appreciated, innovative pre-treatment reactor design for the cost-efficient and highly controlled conversion of lignocellulosic biomass into replacements for conventional fuels and other oil-based materials. The money is supposed to be used for transfering BioGasol's proprietary technology into demonstration scale. The large-scale testing plant will be built in Denmark starting in Q1/2013. "Our new demonstration facility will be co-financed by our industrial partners, SweetWater Energy in the US and a Scandinavian strategic partner," stated BioGasol's CEO Anders Weber.

Biogasol ApS is a Danish biotechnology company. Since its inception in 2006 as a spinout from the Technical University of Denmark, it already has successfully developed a pentose/hexose co-fermentation technology on pilot scale that makes use of metabolically engineered thermophilic bacteria. Biogasol develops so-called 2nd generation bioethanol by focussing on agricultural waste and wood as a source of lignocellulose.

Italian pioneer Chemtex group on the other hand is about to open a US bioethanol plant which will use non-food grasses grown on marginal land. Interestingly, Chemtex relies on the biomass processing enzymes produced by another Danish company, Novozymes. Biogasol is also uses some Novozymes enzymes. However, the company also owns proprietary and patented organisms like a heat-loving thermophilic bacterium isolated 20 years ago from a thermal spring in Iceland or a xylose-converting bacterium.

© eurobiotechnews.eu/ml

http://www.european-biotechnology-news.com/news/news/2012-04/biogasol-attracts-eur15m.html

FinancingBelgium

20.07.2016 Belgian molecular diagnostics company Biocartis Group NV has raised €55m and will use the funds mainly to expand manufacturing capacities for its PCR-based molecular diagnostics system Idylla.

Stock marketsFranceEU

19.07.2016 It is Europe’s first gene therapy company to float on Euronext: Gensight raised €40m in its IPO. And it is not the only French company that has taken the leap in an uncertain market climate – Alzheimer’s expert Pharnext also went public.

ResearchUK

18.07.2016 When NASA blasted off to the International Space Station on Monday morning, it had UK tech on board. A miniature DNA sequencer from Oxford Nanopore will be used to keep an eye on the ISS atmosphere – and may even analyse alien DNA one day.

M&AUKSwitzerland

13.07.2016 Cell Medica has acquired Swiss antibody specialist Delenex Therapeutics. The deal nets the British cellular therapeutics developer Delenex’ proprietory antibody fragment platform Pentrabody.

R&DAustriaFrance

12.07.2016 Vienna-based vaccine specialist Themis Bioscience GmbH has secured broad access to a promising virus vaccine vector tech by extending its license agreement with French Institut Pasteur. Its goal: to develop a Zika vaccine.

M&AFranceEU

07.07.2016 Californian biopharma Medivation has agreed to confidential negotiations with its suitors, in particular the French pharmaceutical company Sanofi, which aggressively has buffeted the cancer therapy specialist for months.

Prenatal DiagnosticsEUUK

06.07.2016 The European Commission started an investigation into Illumina’s and Sequenom’s 2014 patent agreement, UK-competitor Premaitha Health said. The two US companies had agreed to pool their Noninvasive Prenatal Testing IP.

GenericsSpainGermanyEU

04.07.2016 Cinfa Biotech is shuffling for position on the lucrative biosimilar market. The Spanish-German company has published positive results in a study for a pegfilgrastim copycat with 172 healthy volunteers in Germany.

Drug discoveryUKSwitzerland

30.06.2016 UK’s Heptares Therapeutics and Paul Scherrer Institute spinoff leadXpro will collaborate to find new approaches for the determination of high-res X-ray structures of G protein-coupled receptors to find new drugs.

Nuclear medicineNorwayFrance

28.06.2016 Nordic Nanovector has teamed up with Areva Med to develop a treatment for leukaemia. The compound in question is a lead-212 conjugated anti-CD37 antibody.

Quick news provided by GlobeNewswire

View more stock news

Events

All Events

Partner-Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • MOLOGEN (D)1.75 EUR16.67%
  • SWEDISH ORPHAN BIOVITRUM (S)13.11 USD6.59%
  • RENEURON (UK)3.15 GBP5.00%

FLOP

  • VECTURA (UK)148.80 GBP-4.25%
  • BIOTIE THERAPEUTICS (FI)0.27 EUR-3.57%
  • BONE THERAPEUTICS SA (B)16.05 EUR-3.31%

TOP

  • THERAMETRICS (CH)0.05 CHF66.7%
  • PROTHENA PLC (IE)52.22 USD54.5%
  • CLINIGEN GRP (UK)675.00 GBP35.0%

FLOP

  • MOLOGEN (D)1.75 EUR-30.8%
  • EVOCUTIS (UK)0.04 GBP-20.0%
  • SANTHERA (CH)57.15 CHF-17.9%

TOP

  • KARO BIO (S)29.80 SEK1810.3%
  • NICOX (F)11.20 EUR471.4%
  • SAREUM HOLDINGS (UK)0.62 GBP169.6%

FLOP

  • BB BIOTECH (D)45.00 EUR-83.9%
  • NEUROVIVE PHARMACEUTICAL AB (S)4.72 SEK-78.3%
  • EVOCUTIS (UK)0.04 GBP-76.5%

No liability assumed, Date: 26.07.2016